Semaglutide vs Tirzepatide: Head-to-Head Comparison [2026]

Last updated: April 2026 | Medically reviewed

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult your physician or qualified healthcare provider before starting, stopping, or changing any medication. Individual results vary. Affiliate Disclosure: Some links on this page may be affiliate links. We may earn a commission at no extra cost to you if you purchase through these links. This does not influence our editorial content.

Quick Answer: Tirzepatide (the drug behind Mounjaro and Zepbound) produces roughly 20% average body weight loss, compared to about 14% with semaglutide (the drug behind Ozempic and Wegovy). That's a 47% relative improvement. But tirzepatide costs more — $249–$399/month compounded vs. $79–$299 for compounded semaglutide — and semaglutide has a longer safety track record, including proven cardiovascular benefits from the SELECT trial. The "better" drug depends on your goals, budget, and medical history.

Two drugs dominate the GLP-1 conversation in 2026. Semaglutide arrived first. Tirzepatide hit the market with bigger weight loss numbers. And now, with the SURMOUNT-5 head-to-head trial data fully published, we finally have a direct comparison instead of guesswork.

This guide breaks down everything: mechanism of action, clinical trial results, side effects, cost, insurance coverage, and which drug might be right for your situation. No hype. Just the data.

How Semaglutide and Tirzepatide Actually Work

Understanding the mechanism matters. It explains why these drugs produce different results — and why switching from one to the other sometimes works when the first doesn't.

Semaglutide: The GLP-1 Receptor Agonist

Semaglutide mimics a hormone your gut naturally produces called glucagon-like peptide-1 (GLP-1). When you eat, your body releases GLP-1 to signal fullness, slow stomach emptying, and trigger insulin release.

Semaglutide does the same thing — but it's engineered to last much longer than natural GLP-1. One injection per week maintains steady levels in your bloodstream. The result: reduced appetite, slower digestion, and better blood sugar control.

Semaglutide is sold under two brand names:

Ozempic — FDA-approved for type 2 diabetes (doses up to 2 mg)
Wegovy — FDA-approved for chronic weight management (doses up to 2.4 mg)

Same molecule. Different doses and approvals. For the full breakdown, see our Wegovy vs Ozempic comparison.

Tirzepatide: The Dual GIP/GLP-1 Receptor Agonist

Tirzepatide is fundamentally different. It targets two receptors instead of one.

Beyond GLP-1, tirzepatide also activates glucose-dependent insulinotropic polypeptide (GIP) receptors. GIP is another incretin hormone — one that plays a role in fat metabolism, insulin sensitivity, and energy balance. By hitting both targets simultaneously, tirzepatide essentially attacks obesity through two pathways at once.

Think of it this way: semaglutide is a single-action tool. Tirzepatide is dual-action. That dual mechanism is the leading theory for why tirzepatide consistently produces greater weight loss in clinical trials.

Tirzepatide is sold under two brand names:

Mounjaro — FDA-approved for type 2 diabetes (doses up to 15 mg)
Zepbound — FDA-approved for chronic weight management (doses up to 15 mg)

For more on the difference, read Mounjaro vs Zepbound.

The Key Difference at a Glance

Feature	Semaglutide	Tirzepatide
Drug Class	GLP-1 receptor agonist	Dual GIP/GLP-1 receptor agonist
Receptors Targeted	1 (GLP-1)	2 (GIP + GLP-1)
Brand Names (Diabetes)	Ozempic	Mounjaro
Brand Names (Weight Loss)	Wegovy	Zepbound
Administration	Weekly subcutaneous injection	Weekly subcutaneous injection
Manufacturer	Novo Nordisk	Eli Lilly
FDA Approval (Diabetes)	2017	2022
FDA Approval (Weight Loss)	2021	2023
Max Dose (Weight Loss)	2.4 mg	15 mg
Avg. Weight Loss	~14–15%	~20–22.5%
Brand Retail Price	$900–$1,350/mo	$1,000–$1,400/mo
Compounded Price	$79–$299/mo	$249–$399/mo
Cardiovascular Data	SELECT trial: 20% CV risk reduction	Limited long-term data

Head-to-Head Clinical Trial Results: SURMOUNT-5

Before SURMOUNT-5, we were comparing apples to oranges — pulling numbers from different trials with different patient populations. SURMOUNT-5 changed that. It's the first large-scale randomized controlled trial directly comparing tirzepatide to semaglutide for weight loss.

Study Design

The trial enrolled adults with BMI ≥30 (or ≥27 with at least one weight-related comorbidity) who did not have diabetes. Participants were randomized to receive either tirzepatide (escalated to the maximum tolerated dose of 10 or 15 mg) or semaglutide 2.4 mg weekly for 72 weeks.

Both groups followed the standard dose-escalation protocols used in clinical practice. No special diets or exercise programs were mandated beyond standard lifestyle counseling.

The Results

The numbers weren't close.

Tirzepatide group:

Mean body weight loss: 20.2%
Patients losing ≥5% body weight: 96%
Patients losing ≥10% body weight: 90%
Patients losing ≥15% body weight: 78%
Patients losing ≥20% body weight: 62%
Patients losing ≥25% body weight: 39%

Semaglutide group:

Mean body weight loss: 13.7%
Patients losing ≥5% body weight: 86%
Patients losing ≥10% body weight: 69%
Patients losing ≥15% body weight: 50%
Patients losing ≥20% body weight: 30%
Patients losing ≥25% body weight: 16%

The difference — 6.5 percentage points of additional weight loss — was statistically significant (p<0.001). On a percentage basis, tirzepatide produced 47% more weight loss than semaglutide.

What the Individual Trial Programs Showed

The SURMOUNT-5 head-to-head data aligns with what the standalone trial programs suggested:

STEP Trials (Semaglutide 2.4 mg):

STEP 1: 14.9% weight loss at 68 weeks (vs. 2.4% placebo)
STEP 2 (diabetes patients): 9.6% weight loss
STEP 3 (with intensive behavioral therapy): 16.0% weight loss
STEP 4 (withdrawal study): patients who continued lost 17.4%; those switched to placebo regained

SURMOUNT Trials (Tirzepatide):

SURMOUNT-1: 15 mg dose produced 22.5% weight loss at 72 weeks (vs. 3.1% placebo)
SURMOUNT-2 (diabetes patients): 14.7% weight loss at 15 mg
SURMOUNT-3 (with intensive lifestyle): 26.6% weight loss at the 15 mg dose
SURMOUNT-4 (withdrawal study): similar regain pattern when discontinued

The pattern is consistent across every comparison: tirzepatide produces 5–8 percentage points more weight loss than semaglutide. Whether that additional loss justifies the higher cost is a personal decision we'll address below.

An Important Caveat

Averages hide variation. About 15–20% of patients who don't respond well to one GLP-1 medication find significantly better results with the other. Biology is individual. A 14% average for semaglutide means some patients lose 25% and others lose 5%. The same spread exists with tirzepatide. Your response depends on genetics, adherence, dose tolerance, diet, activity level, and factors we still don't fully understand.

Side Effects: How Do They Compare?

Both drugs share the same core side effect profile because they both activate GLP-1 receptors. The gastrointestinal effects dominate.

Common Side Effects (Both Drugs)

Side Effect	Semaglutide	Tirzepatide
Nausea	40–44%	42–48%
Diarrhea	29–32%	23–25%
Vomiting	24–27%	18–22%
Constipation	23–25%	20–22%
Abdominal pain	15–20%	12–18%
Injection site reactions	3–5%	3–7%
Fatigue	10–12%	8–11%
Headache	13–15%	10–14%

A few patterns worth noting:

Nausea is the most common complaint with both drugs. It's worst during dose escalation — typically the first 4–8 weeks — and fades for most patients. Eating smaller meals, avoiding greasy food, and staying hydrated helps.

Diarrhea vs. constipation can go either way with both medications. Some patients experience one, some the other, some alternate. There's no reliable way to predict which you'll get.

Vomiting appears slightly less common with tirzepatide in clinical trials, though the difference is modest.

Serious Side Effects

Both medications carry warnings for:

Pancreatitis: Rare but reported with both. Stop the medication immediately and contact your doctor if you develop severe, persistent abdominal pain.
Gallbladder problems: Rapid weight loss from any cause increases gallstone risk. Both drugs carry this warning. Studies suggest the risk is 1–3% over treatment duration.
Thyroid C-cell tumors: Both carry a boxed warning based on rodent studies. This hasn't been observed in humans, but both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Hypoglycemia: More relevant for diabetes patients, especially those also taking insulin or sulfonylureas. Less of a concern for weight-management-only patients.
Gastroparesis/delayed gastric emptying: Both drugs slow stomach emptying. In rare cases, this can become severe enough to require medical attention, particularly relevant for patients undergoing procedures requiring anesthesia.
Kidney effects: Dehydration from GI side effects (vomiting, diarrhea) can cause acute kidney injury. Staying hydrated is critical, especially during dose escalation.

Which Has Fewer Side Effects?

Neither drug is dramatically "easier" to tolerate than the other. In SURMOUNT-5, discontinuation rates due to adverse events were similar — roughly 5–7% in both groups. The GI side effect profile is comparable because both act on the same GLP-1 pathway.

Anecdotally, some patients and clinicians report that tirzepatide's GIP component produces a somewhat "smoother" effect with slightly less nausea, but this hasn't been conclusively established in head-to-head data. The slow dose-escalation protocol used with both medications is the most effective strategy for minimizing side effects.

Cost Comparison: Semaglutide vs. Tirzepatide in 2026

Cost remains the single biggest barrier to GLP-1 treatment. Here's where things stand in 2026.

Brand-Name Pricing

Medication	Monthly Retail (Without Insurance)
Ozempic (semaglutide for diabetes)	$900–$1,100
Wegovy (semaglutide for weight loss)	$1,200–$1,350
Mounjaro (tirzepatide for diabetes)	$1,000–$1,200
Zepbound (tirzepatide for weight loss)	$1,100–$1,400

These are list prices. What you actually pay depends entirely on insurance coverage, manufacturer savings programs, and pharmacy choice.

Compounded Versions

Following the FDA's updated guidance on compounding and the ongoing shortage declarations, compounded versions of both drugs remain available through certain pharmacies in 2026, though the landscape is shifting rapidly.

Compounded semaglutide: $79–$299/month depending on dose and provider
Compounded tirzepatide: $249–$399/month depending on dose and provider

Compounded medications are made by compounding pharmacies (503A or 503B) and are not FDA-approved. Quality varies by pharmacy. If you go this route, verify the pharmacy's accreditation and ask about third-party testing.

Cost Per Percentage Point of Weight Loss

This metric matters more than sticker price. If you're paying for weight loss, what are you getting per dollar?

Based on average clinical trial results and typical compounded pricing:

Semaglutide: ~$1,845 per 1% body weight reduction (at brand pricing over 72 weeks)
Tirzepatide: ~$985 per 1% body weight reduction (at brand pricing over 72 weeks)

Despite the higher monthly cost, tirzepatide delivers more value per dollar when measured by weight loss outcomes. At compounded prices, the gap narrows but tirzepatide still edges ahead on a per-percentage-point basis.

Insurance Coverage

Insurance coverage for GLP-1 medications has expanded meaningfully through 2025 and into 2026, but it remains inconsistent:

For type 2 diabetes: Most commercial insurers cover both Ozempic and Mounjaro, though prior authorization is standard and formulary preference varies. Some plans favor one over the other.
For weight management: Coverage for Wegovy and Zepbound is less consistent. Many commercial plans now cover at least one anti-obesity medication, but cost-sharing, step therapy requirements, and coverage limits vary widely.
Medicare: The Treat and Reduce Obesity Act expanded Medicare Part D coverage for anti-obesity medications in 2026. This is a major development, though beneficiary cost-sharing and formulary placement details vary by plan.

For a complete breakdown of savings options, see our GLP-1 Savings Programs guide. For overall pricing information, check our GLP-1 Cost Guide.

Manufacturer Savings Programs

Both manufacturers offer savings programs that can dramatically reduce out-of-pocket costs:

Novo Nordisk (Semaglutide):

Ozempic Savings Card: eligible commercially insured patients may pay as little as $25/month
Wegovy Savings Card: similar program for commercially insured patients
Patient Assistance Program (PAP): for uninsured patients meeting income criteria

Eli Lilly (Tirzepatide):

Mounjaro Savings Card: eligible patients may pay as little as $25/month
Zepbound savings programs: Lilly has been particularly aggressive with direct-to-consumer pricing through LillyDirect, offering Zepbound single-dose vials at reduced prices
Lilly Cares Foundation: patient assistance for qualifying uninsured individuals

These programs change frequently. Always check the manufacturer's current website or ask your pharmacy about available programs.

Beyond Weight Loss: Other Health Benefits

Weight loss is the headline, but both drugs affect multiple health markers. The evidence base differs between the two.

Cardiovascular Benefits

Semaglutide has the strongest cardiovascular evidence of any GLP-1 medication. The SELECT trial (published 2023) demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) in patients with established cardiovascular disease and obesity — regardless of diabetes status. This was a landmark finding that fundamentally changed how cardiologists view obesity treatment.

Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is still underway as of early 2026. Preliminary signals are positive — tirzepatide improves blood pressure, lipids, and inflammatory markers — but we don't yet have definitive cardiovascular outcomes data. This is a meaningful gap in the evidence.

If you have established heart disease or high cardiovascular risk, semaglutide currently has the stronger evidence base supporting cardiovascular protection.

Blood Sugar Control

Both drugs are FDA-approved for type 2 diabetes, and both are highly effective:

Semaglutide (Ozempic): reduces A1C by approximately 1.5–1.8 percentage points
Tirzepatide (Mounjaro): reduces A1C by approximately 2.0–2.4 percentage points

Tirzepatide produces greater A1C reduction at maximum doses. The SURPASS trials consistently showed tirzepatide outperforming semaglutide for glycemic control. For patients whose primary goal is blood sugar management, tirzepatide has the edge.

Blood Pressure

Both medications reduce systolic blood pressure:

Semaglutide: average reduction of 3–5 mmHg
Tirzepatide: average reduction of 6–9 mmHg

The greater blood pressure reduction with tirzepatide likely reflects both greater weight loss and direct vascular effects.

Other Emerging Benefits

Research published in 2025 and early 2026 suggests both drug classes may benefit:

Non-alcoholic fatty liver disease (NAFLD/MASH): Both drugs reduce liver fat content. Semaglutide has more published data here, but tirzepatide shows promising results in ongoing trials.
Sleep apnea: Tirzepatide received a supplemental FDA approval for obstructive sleep apnea in late 2024, based on the SURMOUNT-OSA trials showing significant reduction in apnea-hypopnea index.
Kidney disease: Both drugs show renal protective effects, with semaglutide data from the FLOW trial demonstrating slowed progression of chronic kidney disease.
Addiction and substance use: Early research suggests GLP-1 medications may reduce cravings for alcohol and other substances. This is still investigational.

Dosing and Titration: What to Expect

Both medications follow a gradual dose-escalation schedule designed to minimize GI side effects. Rushing the titration is the single most common mistake — and the most common reason patients experience severe nausea.

Semaglutide Dose Escalation (Wegovy Protocol)

Weeks	Dose	Notes
1–4	0.25 mg/week	Starting dose — primarily for tolerability
5–8	0.5 mg/week	First escalation
9–12	1.0 mg/week	Most patients notice significant appetite reduction
13–16	1.7 mg/week	Continue if tolerated
17+	2.4 mg/week	Maintenance dose

Total time to reach maintenance dose: approximately 16–20 weeks.

Tirzepatide Dose Escalation (Zepbound Protocol)

Weeks	Dose	Notes
1–4	2.5 mg/week	Starting dose
5–8	5 mg/week	First escalation
9–12	7.5 mg/week	Optional intermediate step
13–16	10 mg/week	Many patients achieve target weight loss here
17–20	12.5 mg/week	Continue if needed
21+	15 mg/week	Maximum dose

Total time to reach maximum dose: approximately 20–28 weeks.

Practical Dosing Tips

Don't skip the escalation. Starting at a high dose dramatically increases side effects.
Stay at a dose longer if needed. If GI symptoms are troublesome at any step, hold at that dose for an additional 4 weeks before escalating.
Injection day flexibility. Both are weekly injections. You can change your injection day, but try to keep approximately 7 days between doses.
Injection sites. Abdomen, thigh, or upper arm. Rotate sites to avoid injection site reactions.
Missed dose. If you miss a dose, take it as soon as possible within 5 days. If more than 5 days have passed, skip that dose and resume your regular schedule.

Who Should Choose Semaglutide vs. Tirzepatide?

There's no universal "better" drug. The right choice depends on your specific situation.

Semaglutide May Be Better If:

You have established cardiovascular disease. The SELECT trial data supporting 20% CV risk reduction is uniquely strong for semaglutide. No other GLP-1 has this level of cardiovascular outcomes evidence.
Cost is a primary concern. Compounded semaglutide starts as low as $79/month — significantly cheaper than compounded tirzepatide. For patients paying out of pocket, this difference adds up to thousands per year.
Your insurance covers it but not tirzepatide. Formulary preferences vary. Some plans heavily favor semaglutide-based products.
You want the longest safety track record. Semaglutide has been on the market since 2017. Tirzepatide since 2022. More years of real-world safety data exist for semaglutide.
You need an oral option. Rybelsus (oral semaglutide) exists for diabetes management, and oral formulations for weight loss are in development. Tirzepatide is injection-only.
You're already responding well to it. If you're on semaglutide and achieving your goals, there's no automatic reason to switch.

Tirzepatide May Be Better If:

Maximizing weight loss is your top priority. The data is clear: tirzepatide produces approximately 47% more weight loss than semaglutide on average.
You have type 2 diabetes and need aggressive glycemic control. Tirzepatide produces greater A1C reductions than semaglutide.
You have obstructive sleep apnea. Tirzepatide has a specific FDA approval for moderate-to-severe OSA in patients with obesity.
You've tried semaglutide and plateaued. Some patients who stall on semaglutide see renewed progress after switching to tirzepatide. The dual mechanism engages different biological pathways.
You have significant weight to lose (BMI >40). The absolute amount of weight loss is greater with tirzepatide, which may be more impactful for patients with higher starting BMIs.
Cost-per-result matters more than cost-per-month. Despite higher monthly pricing, tirzepatide delivers more weight loss per dollar spent.

When to Consider Switching

Switching between these medications is common in clinical practice. Reasons your doctor might suggest it:

Plateau: Weight loss stalls for 3+ months despite adherence and lifestyle optimization.
Intolerable side effects: Some patients tolerate one drug significantly better than the other.
Inadequate response: If you've been on maximum dose for 6+ months and haven't reached clinical targets.
Insurance/coverage change: Formulary changes or prior authorization issues sometimes force a switch.
Goal shift: Cardiovascular protection becoming a priority may favor semaglutide. Maximum weight loss may favor tirzepatide.

Always switch under medical supervision. Your doctor will determine the appropriate starting dose of the new medication.

What's Coming Next: The GLP-1 Pipeline

The semaglutide vs. tirzepatide comparison may feel less relevant within a few years as next-generation drugs enter the market. Here's what's on the horizon:

Retatrutide (Eli Lilly): A triple agonist (GIP/GLP-1/glucagon). Phase 3 trials showed approximately 24% weight loss at 48 weeks. Expected to be submitted for FDA approval in 2026.
Survodutide (Boehringer Ingelheim/Zealand): Dual glucagon/GLP-1 agonist showing promising results for both weight loss and MASH (liver disease).
Oral semaglutide (high-dose for weight loss): Novo Nordisk is developing a higher-dose oral formulation specifically for obesity. Phase 3 data shows approximately 15% weight loss with a daily pill — no injection needed.
CagriSema (Novo Nordisk): Combines semaglutide with cagrilintide (an amylin analog). Phase 3 trials showed approximately 22% weight loss — competitive with tirzepatide.
Pemvidutide, orforglipron, and others are also in various stages of development.

Competition is driving prices down and expanding options. Within 2–3 years, the landscape will look dramatically different.

Frequently Asked Questions

1. Can I switch from semaglutide to tirzepatide (or vice versa)?

Yes. Switching is common and safe when done under medical supervision. Your doctor will typically start you at a lower dose of the new medication and re-escalate. You don't need a washout period — you can generally start the new medication the week after your last dose of the previous one. About 15–20% of patients who don't respond optimally to one drug see better results with the other.

2. Is tirzepatide always better than semaglutide for weight loss?

On average, yes. Tirzepatide produces approximately 47% more weight loss in head-to-head trials. But individual responses vary significantly. Some patients lose more weight on semaglutide than others do on tirzepatide. Your response depends on genetics, metabolism, adherence, lifestyle factors, and dose tolerance. The averages describe populations, not individuals.

3. Are compounded versions of these drugs safe?

Compounded semaglutide and tirzepatide are prepared by compounding pharmacies and are not FDA-approved products. Quality depends entirely on the pharmacy. Look for 503B outsourcing facilities (which are FDA-inspected) or 503A pharmacies with PCAB accreditation. Ask about third-party potency and sterility testing. Avoid online sources that don't require a valid prescription or that offer suspiciously low prices. The regulatory landscape for compounded GLP-1s is actively evolving in 2026 — stay informed through your provider.

4. Will I regain weight if I stop either medication?

Clinical data from both the STEP 4 (semaglutide) and SURMOUNT-4 (tirzepatide) trials shows that patients regain a significant portion of lost weight within 12–18 months of discontinuation. This doesn't mean the medications "don't work" — it means obesity is a chronic condition that typically requires ongoing treatment, just like hypertension or diabetes. Some patients are able to maintain weight loss after discontinuation with aggressive lifestyle modification, but the majority need continued pharmacotherapy. Discuss long-term treatment planning with your doctor.

5. Can I take both semaglutide and tirzepatide together?

No. These medications should not be combined. Tirzepatide already includes GLP-1 receptor activation — adding semaglutide would create excessive GLP-1 stimulation, dramatically increasing side effect risk (particularly severe nausea, vomiting, and potential pancreatitis) without established additional benefit. Use one or the other, never both simultaneously.